Want to see CRSP full AI Analyst Report?
Top Page
Crispr Therapeutics AG
(NASDAQ:CRSP)
Select Model
Select Model
Rating:51Neutral
Price Target:
$57.00
▼(-1.71% Downside)
Action:Reiterated
Date:06/05/26
The score is held back primarily by weak financial performance (large losses and ongoing cash burn, with rising leverage). Partially offsetting this are a modestly improving technical setup (price above key moving averages) and corporate actions that bolster liquidity and financial flexibility, though valuation remains challenged due to losses and a negative P/E.
Positive Factors
Strengthened liquidity from convertible financing
The $600M convertible notes materially bolstered cash reserves and extends the company’s runway, supporting ongoing late‑stage programs and commercialization activities. This durable funding reduces near‑term financing pressure and enables multi‑period clinical and commercial investments.
Negative Factors
Persistent negative cash flow
Operating cash flow remains meaningfully negative and the company continues to fund operations via reserves and financing rather than internal cash generation. Over months this increases reliance on external capital and creates execution risk if markets or funding terms tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened liquidity from convertible financing
The $600M convertible notes materially bolstered cash reserves and extends the company’s runway, supporting ongoing late‑stage programs and commercialization activities. This durable funding reduces near‑term financing pressure and enables multi‑period clinical and commercial investments.
Read all positive factors
Crispr Therapeutics AG Key Performance Indicators (KPIs)
Any
Revenue by Segment
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might be vulnerable or have opportunities for expansion.
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might be vulnerable or have opportunities for expansion.
Data provided by:
The Fly
The FlyCrispr Therapeutics AG (CRSP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.30B
Dividend YieldN/A
Average Volume (3M)1.65M
Price to Earnings (P/E)―
Beta (1Y)1.83
Revenue Growth-89.11%
EPS Growth-37.55%
CountryUS
Employees393
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.22
Shares Outstanding96,448,790
10 Day Avg. Volume1,592,814
30 Day Avg. Volume1,649,576
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.45
Price to Sales (P/S)1343.50
P/FCF Ratio-13.63
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue1.34K
Enterprise Value/Gross Profit-24.94
Enterprise Value/Ebitda-10.04
Forecast
1Y Price Target
$73.85Price Target Upside27.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.86
Revenue Forecast (FY)$39.04M
Crispr Therapeutics AG Business Overview & Revenue Model
Company Description
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-assoc...
How the Company Makes Money
CRISPR Therapeutics primarily generates revenue from (1) collaboration and partnership arrangements and (2) product-related economics where applicable. A major driver has been its collaboration with Vertex Pharmaceuticals for the CRISPR/Cas9-edite...
Crispr Therapeutics AG Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.10M | 3.51M | 35.00M | 370.00M | 436.00K | 913.08M |
| Gross Profit | -219.96M | -229.45M | -75.25M | 239.75M | -109.81M | 811.90M |
| EBITDA | -546.16M | -558.49M | -343.41M | -130.88M | -626.33M | 397.48M |
| Net Income | -568.53M | -581.60M | -366.25M | -153.61M | -650.17M | 377.66M |
Balance Sheet | ||||||
| Total Assets | 2.73B | 2.27B | 2.24B | 2.23B | 2.24B | 2.75B |
| Cash, Cash Equivalents and Short-Term Investments | 2.44B | 1.98B | 1.90B | 1.69B | 1.82B | 2.38B |
| Total Debt | 787.64M | 394.91M | 223.69M | 238.63M | 244.02M | 225.03M |
| Total Liabilities | 911.26M | 343.43M | 309.95M | 346.77M | 367.58M | 352.42M |
| Stockholders Equity | 1.81B | 1.92B | 1.93B | 1.88B | 1.88B | 2.40B |
Cash Flow | ||||||
| Free Cash Flow | -401.18M | -345.93M | -144.68M | -269.85M | -532.93M | 457.27M |
| Operating Cash Flow | -399.96M | -345.01M | -142.77M | -260.38M | -495.74M | 538.97M |
| Investing Cash Flow | -422.79M | -31.80M | -280.48M | 374.65M | -258.65M | -1.04B |
| Financing Cash Flow | 1.01B | 426.03M | 331.98M | 62.66M | 38.59M | 250.94M |
Crispr Therapeutics AG Technical Analysis
Positive
57.99
Price Trends
52.73
Positive
52.22
Positive
55.55
Negative
Market Momentum
0.54
Negative
56.86
Neutral
65.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Positive. The current price of 57.99 is above the 20-day moving average (MA) of 52.92, above the 50-day MA of 52.73, and above the 200-day MA of 55.55, indicating a neutral trend. The MACD of 0.54 indicates Negative momentum. The RSI at 56.86 is Neutral, neither overbought nor oversold. The STOCH value of 65.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRSP.
Crispr Therapeutics AG Risk Analysis
Crispr Therapeutics AG disclosed 85 risk factors in its most recent earnings report. Crispr Therapeutics AG reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Crispr Therapeutics AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $8.89B | -30.20 | -25.02% | ― | -12.58% | -15.21% | |
53 Neutral | $2.33B | -4.71 | -57.27% | ― | 45.04% | 32.42% | |
53 Neutral | $5.33B | -21.10 | -24.91% | ― | 56.70% | -13.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $5.30B | -8.83 | -30.88% | ― | -89.11% | -37.55% | |
48 Neutral | $3.58B | -54.39 | -5.89% | ― | 157.97% | 86.11% |
* Healthcare Sector Average
CRSP
Crispr Therapeutics AG
54.92
6.28
12.91%
NTLA
Intellia Therapeutics
16.68
7.30
77.83%
BEAM
Beam Therapeutics
34.81
17.80
104.64%
LEGN
Legend Biotech
28.69
-6.80
-19.16%
KYMR
Kymera Therapeutics
108.12
64.48
147.75%
Crispr Therapeutics AG Corporate Events
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Shareholders Approve New Incentive Plan and Governance Measures
Positive
Jun 4, 2026
On June 4, 2026, CRISPR Therapeutics shareholders approved a new 2026 Stock Option and Incentive Plan that rolls over unused shares from prior equity plans and allows a broad range of stock- and cash-based awards, reinforcing the company’s a...
Business Operations and StrategyPrivate Placements and Financing
Crispr Therapeutics Completes $600 Million Convertible Notes Offering
Positive
Mar 16, 2026
On March 16, 2026, CRISPR Therapeutics AG completed a $600 million private offering of Convertible Senior Notes due 2031, including the full exercise of a $50 million option, with an effective coupon of 1.125% that was increased to 1.7308% to offs...
Business Operations and StrategyPrivate Placements and Financing
Crispr Therapeutics Upsizes Convertible Notes Offering to $550 Million
Positive
Mar 11, 2026
On March 10, 2026, CRISPR Therapeutics AG announced plans to privately offer $350 million of convertible senior notes due 2031 to qualified institutional buyers under Rule 144A, with an option for initial purchasers to buy up to an additional $52....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.